Marysia Mullen advises clients at all stages of corporate development on a broad range of executive compensation and employee benefit matters.

Marysia draws on extensive experience to guide public and private company clients, as well as private equity funds, on:

  • Public and emerging company representation, including preparing proxy materials and securities filings related to executive compensation matters and advising companies on proxy advisory and institutional stockholder voting guidelines
  • Negotiating, designing and administrating employment and separation agreements, severance and change in control arrangements, deferred compensation programs, and equity and other incentive compensation plans 
  • Executive compensation and employee benefit aspects of financings, initial public offerings, and other corporate transactions

Marysia also counsels clients on tax, securities, ERISA, and corporate law issues as they relate to executive compensation and employee benefit arrangements.

Marysia’s recent transactional experience includes representing:

  • ATAI Life Sciences on its:
    • US$258.8 million IPO
    • Series C financing
  • Ginkgo Bioworks on its deSPAC and listing on the NYSE
  • Platinum Equity on acquiring Jostens from Newell Brands
  • Vertex on its US$401.9 million IPO
  • VinFast on its deSPAC and listing on the Nasdaq

Bar Qualification

  • District of Columbia
  • New York

Education

  • JD, Syracuse University College of Law, 2013
    summa cum laude, Order of the Coif
  • BA, Boston College, 2008
    summa cum laude